Tennessee Valley Asset Management Partners’s Bristol-Myers Squibb BMY Stock Holding History

Tennessee Valley Asset Management Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-283	Closed	-$14.5K	–	185
2023 Q4	$14.5K	Buy	+283	New	+$14.9K	﹤0.01%	392

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tennessee Valley Asset Management Partners's BMY Position: Q1 2024 in Review

Tennessee Valley Asset Management Partners sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 283 shares — an estimated $14.5K sold.

Tennessee Valley Asset Management Partners first reported a position in BMY in Q4 2023 and held it in 1 quarter. The position peaked at $14.5K in Q4 2023. 2,332 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

Tennessee Valley Asset Management Partners reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
Tennessee Valley Asset Management Partners sold 283 Bristol-Myers Squibb shares in Q1 2024, an estimated $14.5K.
Tennessee Valley Asset Management Partners first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 1 quarter.
Tennessee Valley Asset Management Partners's Bristol-Myers Squibb position peaked at $14.5K in Q4 2023.
2,332 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Tennessee Valley Asset Management Partners's 13F filing for Q1 2024, filed 23 Apr 2024.